With the rapid advancement of medical technology, cell therapy has emerged as a significant breakthrough in modern healthcare, offering new treatment options for many previously hard-to-treat diseases. Celconta Group is at the forefront of this technology, strategically developing two mainstream cell therapies—T-cell therapies (CAR-T, CAR-iT) and NK-cell therapies (PANK, CAR-NK)—and is committed to providing patients with more effective and personalized treatment options.

Currently, Celconta Group has launched CAR-T and PANK clinical trials for solid tumors at several top-tier hospitals. The ongoing clinical trial projects are as follows:

一、CAR-T cell therapy:

T lymphocytes, or T cells, are derived from bone marrow lymphoid stem cells. After differentiating and maturing in the thymus, they circulate through the lymphatic system and blood, distributing throughout the body to perform immune functions in various immune organs and tissues.

CAR-T cell therapy, fully known as Chimeric Antigen Receptor T-cell Immunotherapy, is a precise and targeted treatment method for malignant tumors. It employs genetic engineering technology to modify the patient's autologous T cells, equipping them with Chimeric Antigen Receptors (CAR) that specifically recognize tumor cells. This enables the T cells to efficiently and accurately destroy tumor cells."

CAR-T Cell Therapy Clinical Trial Projects:

1. An Open-Label, Dose-Escalation, Exploratory Clinical Trial of XKDCT225 on the Safety, Efficacy, and Pharmacokinetics in Patients with CLDN18.2-Positive Advanced Solid Malignant Tumors

① Indications: CLDN18.2-positive advanced solid tumors (such as gastric cancer, esophageal cancer, gastroesophageal junction cancer, etc.)

② Drug Name: XKDCT225 Cell Preparation

2. An Open-Label, Dose-Escalation, Exploratory Clinical Trial of XKDCT253 on the Safety, Efficacy, and Pharmacokinetics in Patients with CLDN18.2-Positive Advanced Solid Malignant Tumors

① Indications: CLDN18.2-positive advanced solid tumors (such as gastric cancer, esophageal cancer, gastroesophageal junction cancer, etc.)

② Drug Name: XKDCT253 Cell Preparation

3. An Open-Label, Dose-Escalation, Exploratory Clinical Trial of XKDCT086 on the Safety, Efficacy, and Pharmacokinetics in Patients with CLDN18.2-Positive Advanced Solid Malignant Tumors

① Indications: CLDN18.2-positive advanced solid tumors (such as gastric cancer, esophageal cancer, gastroesophageal junction cancer, etc.)

② Drug Name: XKDCT086 Cell Preparation

4. An Open-Label, Dose-Escalation, Exploratory Clinical Trial of XKDCT341 on the Safety, Efficacy, and Pharmacokinetics in Patients with Nectin-4-Positive Advanced Breast Cancer

① Indications: Nectin-4-positive advanced breast cancer

② Drug Name: XKDCT341 Cell Preparation

5. A Single-Center, Open-Label, Dose-Escalation, Exploratory Clinical Trial of R-Star001 Cell Injection on the Safety, Efficacy, and Pharmacokinetics in Patients with Nectin-4-Positive Advanced Solid Tumors

① Indications: Nectin-4-positive advanced solid tumors (such as breast cancer, urothelial carcinoma, colorectal cancer, etc.) that have failed standard treatments.

② Drug Name: R-Star001 Cell Preparation

二、NK Cell Therapy:

NK cells, or natural killer cells, are a type of lymphocyte capable of non-specifically destroying tumor cells and virus-infected cells without prior sensitization. They play a crucial role as the first line of defense in the human immune system.

PANK: NK Cell Injection Derived from Healthy Donors. This allogeneic NK cell injection is cultured using our proprietary cytokine-based cell culture technology. It is sourced from the peripheral blood of healthy adults aged 18 to 30, with NK cell purity consistently above 95%. Unlike NK cells derived from sources such as umbilical cord blood, these cells exhibit high expression of CD16 and NKG2D, resulting in greater cytotoxic activity against tumor cells. Additionally, the mismatch between inhibitory KIRs (Killer Immunoglobulin-like Receptors) and HLA (Human Leukocyte Antigen) between donor and recipient further enhances killing efficiency.

NK Cell Therapy Clinical Trial Projects:

1. PANK-003 Combined with Postoperative Standard Adjuvant Chemotherapy in Patients with Solid Tumors: A Single-Center, Open-Label, Dose-Escalation, Exploratory Clinical Trial on Safety and Efficacy

① Indications: Patients undergoing standard adjuvant chemotherapy after surgery for solid tumors (such as lung cancer, esophageal cancer, gastric cancer, and breast cancer)

② Drug Name: PANK-003 Cell Preparation

Note: All of the above projects have been approved by the Ethics Committee of the Clinical Research Center. Preliminary research data has demonstrated controlled safety and promising efficacy.

To ensure the scientific rigor and precision of our clinical trials, we have established strict inclusion and exclusion criteria for each project. We warmly welcome eligible patients to participate and join us in the pursuit of safer and more effective treatment methods.

If you or someone you know is interested in participating in our clinical trial projects, please contact us. Our research team will conduct a detailed assessment of your medical condition to determine eligibility for the relevant clinical trial.